A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

Heptares Therapeutics, the GPCR-targeted drug company, and British pharma giant AstraZeneca entered a new collaboration under which AstraZeneca will acquire exclusive global rights on the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate.

Tumour cells have evolved mechanisms to evade the immune system, including through the production of a natural molecule called adenosine. By stimulating A2A receptors, adenosine stops T-cells within the immune system from proliferating and reduces their ability to destroy cancer cells. Blocking A2A receptors can therefore promote the anti-cancer response of T-cells within the tumour microenvironment.


A2A receptor is a G protein-coupled receptor (GPCR) which possess seven transmembrane alpha helices.


Under the terms of the agreement, Heptares will grant AstraZeneca an exclusive license to research, develop, manufacture and commercialise HTL-1071. The companies will also collaborate to discover further A2A receptor-blocking compounds for development in cancer immunotherapy.

Heptares will receive an upfront payment of $10 million (€9m) and is eligible to receive additional, significant near term milestone payments based on agreed pre-clinical and/or clinical events. Subject to successful completion of development and commercialisation milestones, Heptares is also eligible to receive more than $500 million (€457m), as well as up to double-digit tiered royalties on net sales.

Malcolm Weir, Chief Executive Officer of Heptares said: “The A2A receptor programme at Heptares has been an outstanding example of our Structure Based Drug Design approach in action, resulting in a novel clinical candidate, HTL-1071, with a highly attractive profile.”

This agreement is not the first between the British companies. A previous $190m collaboration tied them up to develop small molecule candidates targeting specific G-protein-coupled receptors linked to CNS/pain, cardiovascular/metabolic and inflammatory disorders.

Heptares’ technology targeting GPCRs is also attracting a lot of other partners. Last week, Germany-based MorphoSys extends its collaboration with Heptares to generate new antibody targeting GPCRs. GPCRs stay one of the largest class of pharmaceutical target currently on the market and has still a lot to offer in terms of therapeutic targets.

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.